Research Article
Pharmacological Evaluation of Naproxen Metal Complexes on Antinociceptive, Anxiolytic, CNS Depressant, and Hypoglycemic Properties
Table 2
Central antinociceptive activity of naproxen and its metal chelates at different time intervals.
| Group | Dose (mg/kg) | Reaction time (sec) | 30 min (% elongation) | 60 min (% elongation) | 90 min (% elongation) |
| Control | — | 6.38 ± 0.34 | 5.86 ± 0.46 | 6.12 ± 0.23 | Morphine | 02 | 18.6 ± 0.59 (191.54) | 15.86 ± 0.28 (170.65) | 13.06 ± 0.72 (113.40) | Naproxen | 25 | 9.97 ± 0.52 (56.27) | 11.06 ± 0.45 (88.74) | 10.46 ± 0.70 (70.92) | Naproxen | 50 | 12.12 ± 0.62 (89.97) | 11.94 ± 0.80 (103.75) | 13.3 ± 0.42 (117.32) | Naproxen-copper complex | 25 | 10.8 ± 0.33 (69.28) | 10.8 ± 0.44 (84.30) | 12.4 ± 0.34 (102.61) | Naproxen-copper complex | 50 | 14.62 ± 0.42 (129.15) | 14.8 ± 0.35 (152.56) | 14.52 ± 0.49 (137.25) | Naproxen-cobalt complex | 25 | 11.02 ± 0.48 (72.73) | 11.32 ± 0.53 (93.17) | 11.96 ± 0.50 (95.42) | Naproxen-cobalt complex | 50 | 13.38 ± 0.34 (109.72) | 15.3 ± 0.86 (161.09) | 14.86 ± 0.44 (142.81) | Naproxen-iron complex | 25 | 9.84 ± 0.79 (54.23) | 10.78 ± 0.61 (83.96) | 11.04 ± 0.52 (80.39) | Naproxen-iron complex | 50 | 13.5 ± 0.84 (111.60) | 13.64 ± 0.69 (132.76) | 12.74 ± 0.87 (108.17) | Naproxen-silver complex | 25 | 10.84 ± 0.55 (69.91) | 11.06 ± 0.61 (88.74) | 12.32 ± 0.45 (101.31) | Naproxen-silver complex | 50 | 13.8 ± 0.58 (116.30) | 14.18 ± 0.45 (141.98) | 13.6 ± 0.42 (122.22) | Naproxen-zinc complex | 25 | 12.48 ± 0.29 (95.61) | 12.86 ± 0.51 (119.45) | 12.18 ± 0.54 (99.02) | Naproxen-zinc complex | 50 | 15.38 ± 0.45 (141.07) | 15.44 ± 0.47 (163.48) | 15.12 ± 0.31 (147.06) |
|
|
Each value represents the mean ± SEM (). was considered significant compared with control.
|